AZ has yet to file for approval of Imfinzi in the frontline setting for earlier-stage HCC, despite its well-established role ...

Recordati has received an unsolicited takeover offer from private equity group CVC Capital Partners that, if completed, would ...

His teams are trained to read where it will be three passes from now. In Formula 1, race strategy is no longer a gut call at ...

Trump started the Section 232 probe into pharma in the spring of 2025, using it as a lever for trade negotiations and MFN ...

President Donald Trump has signed an executive order imposing tariffs of up to 100% on imported brandname medicines, unless ...

The Roivant group company said that treatment with batoclimab had shown some improvement in the eye bulging (proptosis) ...

The move comes as Novo Nordisk is experiencing a slowdown in sales growth for Wegovy, with its US revenues from the drug ...

The FDA has approved orforglipron, under the Foundayo trade name, in just 50 days, thanks to a fast track review under the ...

A high burden of infectious diseases coexists with a rapid rise in non-communicable diseases such as diabetes, cancer, and ...

Agios is planning to file its sickle cell disease (SCD) candidate mitapivat with the FDA under the accelerated pathway, based on feedback from the US regulator at a recent meeting. The decision has ...

Top-line results from the OBERON and TITANIA trials showed that tozorakimab reduced the annualised rate of moderate-to-severe ...

In a new episode of the pharmaphorum podcast, recorded at BIO-Europe Spring in Lisbon, Portugal, web editor Nicole Raleigh ...